Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, Yuda Chongpison & Pravit Asawanonda. (2022) On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study. Journal of Dermatological Treatment 33:7, pages 2963-2974.
Read now
Read now
Mona Shahriari, Ryan W. Harrison, Russel Burge, Chen-Yen Lin, William N. Malatestinic, Orin M. Goldblum, Robert R. McLean, Margaux M. Crabtree, Jacqueline O’Brien, Elsie L. Grace & Mwangi J. Murage. (2022) Disease response and patient-reported outcomes among initiators of ixekizumab. Journal of Dermatological Treatment 33:3, pages 1538-1546.
Read now
Read now
Lluís Puig. (2020) The safety of ixekizumab in psoriasis drug therapy. Expert Opinion on Drug Safety 19:2, pages 117-130.
Read now
Read now
Articles from other publishers (15)
Mehrdad Karimi, Anas Zaher, Moshe Bressler & Sabrina Saleem. (2023) Distributive Shock in Erythrodermic Psoriasis Treated With Norepinephrine and Vasopressin: A Case Report. Cureus.
Crossref
Crossref
Benjamin Lockshin, Angel Cronin, Ryan W. Harrison, Robert R. McLean, Laura Anatale‐Tardiff, Russel Burge, Baojin Zhu, William N. Malatestinic, Bilal Atiya, Mwangi J. Murage, Gaia Gallo, Bruce Strober & Abby Van Voorhees. (2021) Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 34:2.
Crossref
Crossref
Jashin J Wu, Ryan W Harrison, Baojin Zhu, Orin M Goldblum, William N Malatestinic, Russel Burge & Mwangi J Murage. (2021) Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry. Journal of Comparative Effectiveness Research 10:2, pages 157-167.
Crossref
Crossref
E.V. Svechnikova, Z.B. Marshani, K.A. Fomin & E.Yu. Evdokimov. (2021) Genetically engineered biological drugs in psoriasis treatment in the COVID-19 pandemic. Klinicheskaya dermatologiya i venerologiya 20:5, pages 95.
Crossref
Crossref
Sandro C. Furiati, Jonatas S. Catarino, Marcos V. Silva, Rafaela F. Silva, Rayane B. Estevam, Reginaldo B. Teodoro, Sanivia L. Pereira, Meire Ataide, Virmondes RodriguesJr.Jr. & Denise B. R. Rodrigues. (2019) Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients. Scientific Reports 9:1.
Crossref
Crossref
Zahra Omidian, Rizwan Ahmed, Adebola Giwa, Thomas Donner & Abdel Rahim A. Hamad. (2019) IL-17 and limits of success. Cellular Immunology 339, pages 33-40.
Crossref
Crossref
Claudio Guarneri, Mohammed Aguennouz, Fabrizio Guarneri, Francesca Polito, Salvatore Benvenga & Serafinella Patrizia Cannavò. (2018) Autoimmunität gegen heterogenes nukleäres Ribonukleoprotein A1 bei Psoriasispatienten und Korrelation mit dem Schweregrad der Erkrankung. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 16:9, pages 1103-1108.
Crossref
Crossref
Claudio Guarneri, Mohammed Aguennouz, Fabrizio Guarneri, Francesca Polito, Salvatore Benvenga & Serafinella Patrizia Cannavò. (2018) Autoimmunity to heterogeneous nuclear ribonucleoprotein A1 in psoriatic patients and correlation with disease severity. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 16:9, pages 1103-1107.
Crossref
Crossref
Lian Cui, Rongfen Chen, Smriti Subedi, Qian Yu, Yu Gong, Zeyu Chen & Yuling Shi. (2018) Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials. International Immunopharmacology 62, pages 46-58.
Crossref
Crossref
Olga Ucar. (2018) Delivering Precision Medicine and Patient-Centred Care Through a Multidisciplinary Approach. European Medical Journal, pages 17-24.
Crossref
Crossref
Maria-Isabela Sârbu, Simona-Roxana Georgescu, Mircea Tampa, Alexandra-Elena Sârbu & Olga Simionescu. (2018) Biological therapies in psoriasis - revisited. Romanian Journal of Internal Medicine 56:2, pages 75-84.
Crossref
Crossref
Iris M. Otani, Amy S. Levin & Aleena Banerji. (2018) Cutaneous Manifestations of Reactions to Biologics. Current Allergy and Asthma Reports 18:2.
Crossref
Crossref
C. Paul, L. Guenther, H. Torii, H. Sofen, R. Burge, C.Y. Lin, A. Potts Bleakman, L. Mallbris & Y. Poulin. (2018) Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. Journal of the European Academy of Dermatology and Venereology 32:1, pages 68-72.
Crossref
Crossref
Shiying Shao, Xuefeng Yu & Liya Shen. (2018) Autoimmune thyroid diseases and Th17/Treg lymphocytes. Life Sciences 192, pages 160-165.
Crossref
Crossref
Zeyu Chen, Yu Gong & Yuling Shi. (2017) Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis. Clinical Drug Investigation 37:10, pages 891-899.
Crossref
Crossref